Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers

Neurobiol Aging. 2013 Jan;34(1):73-82. doi: 10.1016/j.neurobiolaging.2012.03.010. Epub 2012 Apr 18.

Abstract

Medial temporal lobe atrophy (MTA) and cerebrospinal fluid (CSF) markers of Alzheimer's disease (AD) pathology may aid the early detection of AD in mild cognitive impairment (MCI). However, the relationship between structural and pathological markers is not well understood. Furthermore, while posterior atrophy (PA) is well recognized in AD, its value in predicting conversion from late-onset amnestic MCI to AD is unclear. In this study we used visual ratings of MTA and PA to assess their value in predicting conversion to AD in 394 MCI patients. The relationship of atrophy patterns with CSF Aβ1-42, tau, and p-tau(181) was further investigated in 114 controls, 192 MCI, and 99 AD patients. There was a strong association of MTA ratings with conversion to AD (p < 0.001), with a weaker association for PA ratings (p = 0.047). Specific associations between visual ratings and CSF biomarkers were found; MTA was associated with lower levels of Aβ1-42 in MCI, while PA was associated with elevated levels of tau in MCI and AD, which may reflect widespread neuronal loss including posterior regions. These findings suggest both that posterior atrophy may predict conversion to AD in late-onset MCI, and that there may be differential relationships between CSF biomarkers and regional atrophy patterns.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Atrophy / cerebrospinal fluid
  • Atrophy / diagnosis
  • Atrophy / etiology
  • Biomarkers / cerebrospinal fluid*
  • Brain / pathology*
  • Cognitive Dysfunction / cerebrospinal fluid*
  • Cognitive Dysfunction / complications
  • Cognitive Dysfunction / diagnosis*
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Observation / methods*
  • Peptide Fragments / cerebrospinal fluid*
  • Predictive Value of Tests
  • Severity of Illness Index
  • Statistics, Nonparametric

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)